LTRN Lantern Pharma Inc. Insider Trading

Director Schalop Lee Troy bought 48,544 shares of LTRN at $2.06 ($100.0K) on 2026-05-12; stock up +34.3% in 30 days amid unprofitability.

Director Schalop Lee Troy's $100.0K purchase of 48,544 shares at $2.06 represents meaningful personal capital commitment during a period of company unprofitability (net income: $-4.2M) and low absolute valuation (market cap $35.4M). The 30-day price appreciation of +34.3% since the purchase date suggests either positive market sentiment diverging from fundamentals or opportunistic timing during a depressed period. However, the company remains deeply unprofitable, and the director's acquisition signal must be weighed against the fundamental operational challenges reflected in negative net income. This single director buy represents a conviction signal, though in an early-stage biotech environment characterized by significant volatility (52-week range $1.11–$5.74).

Director D Jeffrey Keyser buys 48.5K shares of LTRN at $2.06; stock up 34.3% in 30 days but down 45.5% from 52-week high

Director D Jeffrey Keyser's $100.0K purchase of 48.5K shares at $2.06 represents a meaningful commitment during a period of stock volatility—the company trades 45.5% below its 52-week high of $5.74 yet has rallied +34.3% over the past 30 days. This insider buy occurs while Lantern Pharma faces structural unprofitability with net income of $-4,177,423.00 against a modest market cap of $35.4M, suggesting the director sees value despite current losses. The timing signal is mixed: the 30-day momentum is positive, but the persistent discount to recent highs and negative fundamentals warrant scrutiny as to whether this reflects conviction in turnaround prospects or a bottom-fishing move at cyclical lows.